Artwork

Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.
Player FM - Podcast App
Go offline with the Player FM app!

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer

11:42
 
Share
 

Manage episode 331563801 series 2947447
Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Rick Greene, MD, and Mark Truty, MD, discuss the role of neoadjuvant chemotherapy in the treatment of pancreatic cancer, including the optimal treatment of patients who do not respond to first-line chemotherapy or develop toxicities. Dr. Truty is author of, “Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.” Dr. Truty is Associate Professor of Surgery, Mayo Clinic, Rochester, MN, where his clinical practice is in the Division of Subspecialty General Surgery, Department of Surgery.

  continue reading

58 episodes

Artwork
iconShare
 
Manage episode 331563801 series 2947447
Content provided by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology. All podcast content including episodes, graphics, and podcast descriptions are uploaded and provided directly by Annals of Surgical Oncology and Society of Surgical Oncology, Annals of Surgical Oncology, and Society of Surgical Oncology or their podcast platform partner. If you believe someone is using your copyrighted work without your permission, you can follow the process outlined here https://player.fm/legal.

Rick Greene, MD, and Mark Truty, MD, discuss the role of neoadjuvant chemotherapy in the treatment of pancreatic cancer, including the optimal treatment of patients who do not respond to first-line chemotherapy or develop toxicities. Dr. Truty is author of, “Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer.” Dr. Truty is Associate Professor of Surgery, Mayo Clinic, Rochester, MN, where his clinical practice is in the Division of Subspecialty General Surgery, Department of Surgery.

  continue reading

58 episodes

All episodes

×
 
Loading …

Welcome to Player FM!

Player FM is scanning the web for high-quality podcasts for you to enjoy right now. It's the best podcast app and works on Android, iPhone, and the web. Signup to sync subscriptions across devices.

 

Quick Reference Guide